Shares of Juno Therapeutics (NASDAQ: JUNO) a clinical-stage biotech focused on CAR-T cancer immunotherapies, rose 12.1% during April, according to data from S&P Global Market Intelligence. Juno didn't ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results